AR029858A1 - Derivados de indol - Google Patents
Derivados de indolInfo
- Publication number
- AR029858A1 AR029858A1 ARP010103457A ARP010103457A AR029858A1 AR 029858 A1 AR029858 A1 AR 029858A1 AR P010103457 A ARP010103457 A AR P010103457A AR P010103457 A ARP010103457 A AR P010103457A AR 029858 A1 AR029858 A1 AR 029858A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- trifluoromethylsulfonyl
- alkylsulfonyl
- cycloalkyl
- alkylthio
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title abstract 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 6
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- -1 cyano, nitro, amino, hydroxy Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 229910002091 carbon monoxide Inorganic materials 0.000 abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 150000002475 indoles Chemical class 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003441 thioacyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Se refiere a un indol sustituido que deriva de la formula (1) en los cuales R1 es hidrogeno o alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquilo C1-6-alquilo C1-6, todos los cuales pueden sustituirse una o más veces con sustituyentes seleccionados de halogeno, ciano, nitro, amino, hidroxi, tiol, alcoxi C1-6, alquiltio, C1-6, trifluorometilo, trifluormetilsulfonilo, y alquilsulfonilo C1-6, o R1 es arilo, arilalquilo C1-6, heteroarilo y heteroarilalquilo C1-6, en los cuales los grupos arilo y heteroarilo pueden sustituirse una o más veces con sustituyentes seleccionados de halogeno, ciano, nitro, amino, alquilo C1-6, alcoxi C1-6, alquiltio C1-6, hidroxi, tiol, trifluorometilo, trifluorometilsulfonilo y alquilsulfonilo C1-6 o R1 es ûNR'R" que se seleccionan en forma independiente de hidrogeno alquilo C1-6, arilo, arilalquilo C1-6, heteroarilalquilo C1-6 todos los cuales pueden sustituirse una o más veces con sustituyentes seleccionados de halogeno, ciano, nitro, amino, alquilo C1-6, alcoxi C1-6, alquiltio C1-6, hidroxi, tiol, trifluorometilo, trifluorometilsulfonilo y alquilsulfonilo C1-6, o R1 un anillo de 5 a 6 elementos saturado o parcialmente saturado que contiene uno, dos o tres átomos seleccionados de O, S y un grupo N-R9 en el cual R9 es hidrogeno o alquilo C1-6, sustituido en forma opcional con sustituyentes seleccionados de halogeno, ciano, nitro, amino, alcoxi C1-6, alquiltio C1-6, hidroxi, tiol, trifluorometilo, trifluorometilsulfonilo, y alquilsulfonilo C1-6; W es un enlace, o W es un grupo O, S, CO, CS, SO, o SO2; n es 0-6, m es 0-6 y n + m es 0-6; siempre y cuando W es O, o S, n = 2 y cuando W es CO, CS, SO, o SO2, n = 1; X es C, CH, o N y la línea de puntos que emana de X indica un enlace cuando X es C y ningun enlace cuando X es N o CH; R2 es alquilo C1-6; R3 - R7 se seleccionan de hidrogeno, halogeno, ciano, nitro, amino, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquilo C3-8 alquilo C1-6, alcoxi C1-6, alquiltio C1-6, hidroxi, tiol, trifluorometilo, trifluorometilsulfonilo y alquilsulfonilo C1-6; R8 es hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquilo C3-8 alquilo C1-6, arilo, arilalquilo C1-6, acilo, tioacilo, alquilsulfonilo C1-6, trifluorometilsulfonilo, o arilsulfonilo, o una de sus sales de adicion ácida aceptables para uso farmacéutico. Los compuestos de la invencion son potentes ligandos D4 de dopamina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200001123 | 2000-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR029858A1 true AR029858A1 (es) | 2003-07-16 |
Family
ID=8159625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010103457A AR029858A1 (es) | 2000-07-21 | 2001-07-20 | Derivados de indol |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6743809B2 (es) |
| EP (1) | EP1305307B1 (es) |
| JP (1) | JP2004504396A (es) |
| KR (1) | KR100851793B1 (es) |
| CN (1) | CN1264838C (es) |
| AR (1) | AR029858A1 (es) |
| AT (1) | ATE266024T1 (es) |
| AU (2) | AU8173801A (es) |
| BG (1) | BG107528A (es) |
| BR (1) | BR0112998A (es) |
| CA (1) | CA2416212C (es) |
| CZ (1) | CZ301114B6 (es) |
| DE (1) | DE60103162T2 (es) |
| EA (1) | EA004749B1 (es) |
| ES (1) | ES2219554T3 (es) |
| HR (1) | HRP20030015A2 (es) |
| HU (1) | HUP0302820A3 (es) |
| IL (2) | IL153605A0 (es) |
| IS (1) | IS2172B (es) |
| MX (1) | MXPA02012927A (es) |
| NO (1) | NO323799B1 (es) |
| NZ (1) | NZ523436A (es) |
| PT (1) | PT1305307E (es) |
| SK (1) | SK286701B6 (es) |
| TR (1) | TR200401488T4 (es) |
| UA (1) | UA73995C2 (es) |
| WO (1) | WO2002008223A1 (es) |
| ZA (1) | ZA200300287B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0416665A (pt) | 2003-11-17 | 2007-01-16 | Boehringer Ingelheim Int | indóis substituìdos com piperidina ou heteroderivados dos mesmos |
| TWI391387B (zh) * | 2004-05-12 | 2013-04-01 | Eisai R&D Man Co Ltd | 具有哌啶環之吲哚衍生物 |
| EP1994019B1 (en) | 2005-04-30 | 2011-11-02 | Boehringer Ingelheim International GmbH | Novel piperidin - substituted indoles and their use as ccr-3 modulators |
| JP5581055B2 (ja) | 2006-10-27 | 2014-08-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピペリジル−プロパン−チオールｃｃｒ３モジュレーター |
| CN101486654B (zh) * | 2009-03-04 | 2012-10-10 | 西安近代化学研究所 | 2-甲基-3-硝基苯乙酸合成方法 |
| CN110041318B (zh) * | 2018-01-17 | 2022-07-29 | 中国科学院上海药物研究所 | 一类多巴胺d5受体激动剂及其制备和应用 |
| CN110498789B (zh) * | 2018-05-17 | 2022-04-05 | 上海医药工业研究院 | 芳烷哌啶类衍生物及其在多靶点抗抑郁症中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2322470A1 (de) * | 1973-05-04 | 1974-11-21 | Boehringer Sohn Ingelheim | Neue indolyl-piperidino-(bzw. 1,2,5,6tetrahydro-pyridyl-)butyrophenone und verfahren zu ihrer herstellung |
| AT332401B (de) * | 1973-11-26 | 1976-09-27 | Roussel Uclaf | Verfahren zur herstellung von neuen (4'-(3''-indolyl)-piperidino)-alkylarylketonderivaten |
| JPH0633252B2 (ja) * | 1987-08-13 | 1994-05-02 | グラクソ、グループ、リミテッド | インドール誘導体 |
| GB8719167D0 (en) * | 1987-08-13 | 1987-09-23 | Glaxo Group Ltd | Chemical compounds |
| WO1994003444A1 (en) * | 1992-08-05 | 1994-02-17 | John Wyeth & Brother Limited | Amide derivatives |
| HUT73807A (en) * | 1993-04-22 | 1996-09-30 | Pfizer Res & Dev | 5-ht1-like indole derivatives and pharmaceutical compositions containing them |
| ES2063700B1 (es) * | 1993-04-28 | 1995-07-16 | Vita Invest Sa | Agente activo sobre el sistema nervioso central, proceso para su preparacion y composiciones farmaceuticas que lo contengan. |
| US5576321A (en) * | 1995-01-17 | 1996-11-19 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| GB9718712D0 (en) * | 1997-09-03 | 1997-11-12 | Merck Sharp & Dohme | Theraputic Agents |
-
2001
- 2001-07-17 ES ES01960182T patent/ES2219554T3/es not_active Expired - Lifetime
- 2001-07-17 UA UA2003010167A patent/UA73995C2/uk unknown
- 2001-07-17 NZ NZ523436A patent/NZ523436A/en unknown
- 2001-07-17 EP EP01960182A patent/EP1305307B1/en not_active Expired - Lifetime
- 2001-07-17 IL IL15360501A patent/IL153605A0/xx unknown
- 2001-07-17 CZ CZ20030196A patent/CZ301114B6/cs not_active IP Right Cessation
- 2001-07-17 BR BR0112998-8A patent/BR0112998A/pt not_active IP Right Cessation
- 2001-07-17 HR HR20030015A patent/HRP20030015A2/hr not_active Application Discontinuation
- 2001-07-17 MX MXPA02012927A patent/MXPA02012927A/es active IP Right Grant
- 2001-07-17 EA EA200300179A patent/EA004749B1/ru not_active IP Right Cessation
- 2001-07-17 PT PT01960182T patent/PT1305307E/pt unknown
- 2001-07-17 JP JP2002514129A patent/JP2004504396A/ja active Pending
- 2001-07-17 SK SK203-2003A patent/SK286701B6/sk not_active IP Right Cessation
- 2001-07-17 AU AU8173801A patent/AU8173801A/xx active Pending
- 2001-07-17 KR KR1020037000850A patent/KR100851793B1/ko not_active Expired - Fee Related
- 2001-07-17 WO PCT/DK2001/000507 patent/WO2002008223A1/en not_active Ceased
- 2001-07-17 CN CNB018151078A patent/CN1264838C/zh not_active Expired - Fee Related
- 2001-07-17 AU AU2001281738A patent/AU2001281738B2/en not_active Ceased
- 2001-07-17 DE DE60103162T patent/DE60103162T2/de not_active Expired - Fee Related
- 2001-07-17 TR TR2004/01488T patent/TR200401488T4/xx unknown
- 2001-07-17 HU HU0302820A patent/HUP0302820A3/hu unknown
- 2001-07-17 CA CA002416212A patent/CA2416212C/en not_active Expired - Fee Related
- 2001-07-17 AT AT01960182T patent/ATE266024T1/de not_active IP Right Cessation
- 2001-07-20 AR ARP010103457A patent/AR029858A1/es unknown
-
2002
- 2002-12-23 IS IS6663A patent/IS2172B/is unknown
- 2002-12-24 IL IL153605A patent/IL153605A/en not_active IP Right Cessation
-
2003
- 2003-01-10 ZA ZA200300287A patent/ZA200300287B/en unknown
- 2003-01-10 NO NO20030127A patent/NO323799B1/no not_active IP Right Cessation
- 2003-01-17 US US10/347,574 patent/US6743809B2/en not_active Expired - Fee Related
- 2003-02-05 BG BG107528A patent/BG107528A/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057987A1 (es) | Compuestos agonistas de cb1 (receptor cannabinoide) | |
| AR054799A1 (es) | Derivados de oxindol | |
| ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
| CO5590895A2 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| NO20032252L (no) | Piperazinylpyrazinforbindelser som agonist eller antagonist av serotonin 5HT-2-reseptor | |
| AR050430A1 (es) | Analogos de dipeptidos inhibidores de la hepatitis c | |
| AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
| AR063015A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
| AR039868A1 (es) | Inhibidores selectivos de la enzima kalikreina plasmatica | |
| ES2422204T3 (es) | Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS) | |
| ES2184280T3 (es) | Compuestos de indol como inhibidores de cox-2'. | |
| ECSP055974A (es) | Síntesis de cloruros de 4 amino-2-butenoil y su uso en la preparación de 3-ciano quinolinas | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
| AR061835A1 (es) | Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR039988A1 (es) | Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos | |
| AR052915A1 (es) | Derivados de pirrolidin y piperidin acetileno | |
| AR029858A1 (es) | Derivados de indol | |
| AR045326A1 (es) | Derivados de aminoquinolina y su uso como ligandos a3 de adenosina | |
| BRPI0411308A (pt) | composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |